# Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896)

> **NCT01190254** · PHASE3 · COMPLETED · sponsor: **Organon and Co** · enrollment: 306 (actual)

## Conditions studied

- Schizophrenia, Paranoid
- Schizophrenia, Disorganized
- Schizophrenia, Undifferentiated

## Interventions

- **DRUG:** asenapine 2.5 mg
- **DRUG:** asenapine 5.0 mg
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01190254
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09-28
- **Primary completion:** 2013-03-10
- **Final completion:** 2013-04-01
- **Target enrollment:** 306 (ACTUAL)
- **Last updated:** 2024-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01190254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01190254, "Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896)". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01190254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*